{"entity":{"id":"nct04895358","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Doxorubicin and Capecitabine in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) is a phase 3 interventional study registered as NCT04895358 by Merck Sharp & Dohme LLC, with 342 participants enrolled, started 2021-06-18 and due to reach its primary completion in 2026-04-24. Interventions recorded: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine and normal saline.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04895358","url":"https://clinicaltrials.gov/study/NCT04895358"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","doxorubicin","capecitabine"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04895358","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)","sponsor":"Merck Sharp & Dohme LLC","enrolled":342,"outcomes":[]},"route":"/trials/nct04895358/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}